Group 1 - Huazhong Securities has been approved to issue subordinate corporate bonds with a total face value of no more than 10 billion yuan [1] - Jinbei Automotive plans to invest 240 million yuan to establish an automotive industry investment fund focusing on electrification, intelligence, and low carbon [1] - Linyang Energy is expected to win a bid for a 244 million yuan metering equipment project from Southern Power Grid [1][2] Group 2 - Renfu Pharmaceutical's subsidiary has received drug registration certificates for two products, including a medication for acute hypotension [3][4] - Nanjing Steel plans to distribute a cash dividend of 0.1186 yuan per share [5][6] - Pairui Co. has signed a strategic cooperation agreement with Xi'an Power Electronics Research Institute to develop power devices [7][8] Group 3 - Haixing Electric is expected to win a bid for a 214 million yuan metering equipment project from Southern Power Grid [9][10] - Kuangda Technology is planning a change in control, leading to a continued suspension of its stock [11][12] - Samsung Medical is expected to win a bid for a 274 million yuan metering equipment project from Southern Power Grid [13][14] Group 4 - Jiukang Bio has obtained a medical device registration certificate for a specific diagnostic kit [15][16] - Hechuan Technology's minority shareholder plans to transfer a 13% stake in a subsidiary [17][18] - DiAo Micro has launched a new eUSB2 repeater product for various electronic applications [19][20] Group 5 - David Medical's electric surgical table registration application has been accepted [21][22] - Hangxin Technology plans to apply for a total of 280 million yuan in bank credit [23][24] - Liyuan Technology's non-independent director has resigned [25][26] Group 6 - Ningbo Construction's subsidiary has won a construction project bid worth 729 million yuan [27][28] - Huaren Pharmaceutical's subsidiary has received approval for a raw material drug [29][30] - Suwen Electric plans to distribute a cash dividend of 1 yuan per 10 shares [31][32] Group 7 - Solar Energy has received 1.692 billion yuan in renewable energy subsidies [33][34] - Wangli Security has obtained a patent for a new lock structure [35][36] - Zhejiang Energy's vice chairman has resigned due to age reasons [37][38] Group 8 - Beilu Pharmaceutical's subsidiary has passed GMP certification in Brazil [39][40] - Zhejiang Communications has a subsidiary that is expected to win a highway project bid [41][42] - Xinzhi Group has received a government subsidy of 11.1978 million yuan [43][44] Group 9 - Dong'an Power's engine sales in August increased by 3.44% year-on-year [45][46] - Baiyun Mountain's subsidiary has passed the consistency evaluation for two generic drugs [47][48] - Yipin Hong's subsidiary has received a drug registration certificate for a specific injection [49][50] Group 10 - Far East Holdings' subsidiary has won multiple contracts totaling 1.689 billion yuan [51][52] - Good Housekeeping's shareholder plans to reduce holdings by up to 3.5 million shares [53][54] - Guanghong Technology's shareholders have set a transfer price of 23.33 yuan per share [55][56] Group 11 - Keli Sensor plans to acquire 45% of Huahong Technology's shares for 122 million yuan [57][58] - Jianmin Group's furosemide oral solution has been approved for market launch [59][60] - Jinghua Laser's directors plan to reduce their holdings by up to 143,420 shares [61][62] Group 12 - Zhuyue Group is planning a share transfer that will change its controlling shareholder [63][64] - Terid has pre-bid for two projects totaling approximately 698 million yuan [65][66] - Zhonghuan Hailu is planning a change in control, leading to a continued suspension of its stock and convertible bonds [67][68] Group 13 - Great Wall Motors reported August sales of 115,600 vehicles, a year-on-year increase of 22.33% [69][70] - Guizhou Tire's controlling shareholder has committed not to reduce holdings for 12 months [71][72] - San Da Membrane's shareholder plans to reduce holdings by up to 1% of the company's shares [73][74] Group 14 - Chint Electric has decided to terminate the spin-off of its subsidiary for listing [75][76] - Jusaylong's shareholder plans to reduce holdings by up to 1% of the company's shares [77][78]

Group 1 - The core point of the announcement is that Jianmin Pharmaceutical Group has received approval for the oral solution of Furosemide, which is a diuretic used for treating edema and hypertension [1][2]. - The drug is classified as a prescription medication and is registered as a Class 3 chemical drug in China, with a shelf life until August 25, 2030 [1][2]. - The oral solution form of Furosemide is particularly suitable for children, enhancing medication safety and compliance compared to traditional tablet and injection forms [2]. Group 2 - The total research and development investment for the Furosemide oral solution reached approximately RMB 8.0523 million as of July 31, 2025 [2]. - In the Chinese market, Furosemide has various formulations, including tablets and injections, with sales figures for Furosemide reaching RMB 690 million in 2022, RMB 735 million in 2023, and RMB 603 million in 2024 [3]. - The approval of the Furosemide oral solution is expected to enrich the company's product line and enhance its core competitiveness, although short-term impacts on financial performance are anticipated to be limited [3].

Group 1 - The core point of the article is that Jianmin Group has received approval from the National Medical Products Administration for its furosemide oral solution to be marketed [2] Group 2 - The announcement was made on the evening of September 1 [2] - The approval signifies a significant milestone for the company's product development and market entry [2]

Core Viewpoint - The approval of the oral solution of Furosemide by Jianmin Group represents a significant advancement in the treatment options for conditions such as heart failure, liver cirrhosis, and kidney-related edema, as well as hypertension [1] Company Summary - Jianmin Group has received approval from the National Medical Products Administration for its Furosemide oral solution [1] - The oral solution is a high-efficiency diuretic, which is more suitable for children compared to traditional tablet and injection forms, enhancing medication safety and adherence [1] - The developed product has the same active ingredients, excipients, dosage form, specifications, indications, administration routes, and dosages as the reference original preparation, indicating its clinical application value [1] Industry Summary - The introduction of the oral solution will provide more treatment options in the relevant disease areas, potentially impacting the market for diuretics and related medications [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its oral solution of Furosemide, a potent diuretic used for treating edema related to heart failure, liver cirrhosis, and kidney diseases, as well as hypertension [1] Group 1 - The oral solution formulation is more suitable for children compared to traditional tablet and injection forms, enhancing medication safety and adherence [1]